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Effects of sodium nitroprusside on hemodialysis-induced plate- utes from its intracellular storage sites to the surface of
let activation. activated platelets [2, 3] and of activated endothelial cells
Background. Hemodialysis (HD) is associated with increased [4, 5]. Expression of P-selectin on platelets is followedplatelet activation as reflected by enhanced P-selectin expres-
by rapid release of a soluble (c)P-selectin into the super-sion on platelets and by increased formation of heterotypic
natant ex vivo [2, 3] and in vivo [6].platelet-leukocyte aggregates. Both may play a pathophysio-
logic role in HD-associated platelet dysfunction or the propaga- As P-selectin appears to play a role in early atheroscle-
tion of atherosclerosis. As nitric oxide (NO) is a potent inhibi- rosis [7, 8], mechanisms that down-regulate P-selectin
tor of platelet activation, we were interested in whether HD- expression and its release have become a focus of scien-induced platelet activation could be blunted by a NO donor.
tific interest.Methods. After a pilot study in 12 patients to gain an esti-
A clinical situation that is associated with increasedmate for the sample size, the main trial was conducted as a
randomized, double-blind, placebo-controlled, two-way, cross- expression of P-selectin on platelets is hemodialysis
over study. Twelve patients received an infusion of sodium (HD) [9–11]. The number of platelets expressing P-selec-
nitroprusside (1 mg/kg/min for over 15 min) or placebo into tin increases as early as five minutes after the start ofthe inlet port of the HD device.
HD [9, 12].Results. Platelet activation increased within five minutes
Others showed that heterotypic platelet-leukocyte ag-after start of HD (P , 0.05). Infusion of sodium nitroprusside
neither decreased platelet activation (P-selectin1 platelets) nor gregates form during HD [13]. However, no increase
affected the number of platelet-leukocyte aggregates (CD411 was seen in the systemic circulation, possibly indicating
neutrophils) as measured by flow cytometry.
sequestration of these aggregates in the human body.Conclusion. Although NO may have inhibitory effects on
These aggregates have recently been found in a numberplatelet activation in vivo, our results confirm recent findings
of cardiovascular diseases as well as in sepsis [14]. Moreshowing that NO donors were ineffective in preventing platelet
activation by extracorporeal circulation during cardiopulmo- directly related to HD is the finding that hydrogen perox-
nary bypass or plateletpheresis. Thus, NO donors do not appear ide formation increased in the first 20 minutes of dialysis
to be ideal candidate drugs to inhibit HD-associated platelet
in neutrophils aggregated to platelets, but not in neutro-activation.
phils not aggregated to platelets. Similar effects were
observed in vitro when adenosine diphosphate-activated
platelets were incubated with neutrophils but wereThe adhesion molecule P-selectin is stored in the Wei-
largely inhibited by addition of anti-P-selectin antibody.bel-Palade bodies of endothelial cells and in the a gran-
These results strongly suggest that platelet-neutrophilules of platelets [1]. P-selectin is translocated within min-
aggregates during HD may have relevant pathophysio-
logical effects. Finally, the HD-induced leukocyte mar-
gination has recently been demonstrated to correlate
1 TARGET is The Adhesion Research Group Elaborating Therapeutics with increased expression of the oligosaccharide sialyl-
Lewis 3 (CD15s) on leukocytes. The increased expres-Key words: P-selectin, artherosclerosis, nitric oxide, platelet dysfunc-
tion, dialysis, pulmonary dysfunction. sion of CD15s on leukocytes was accompanied by in-
creased binding of its counter receptor, P-selectin, toReceived for publication June 29, 1998
monocytes and polymorphonuclear cells [12]. This cell-and in revised form September 16, 1998
Accepted for publication September 16, 1998 bound cP-selectin may derive from the release of a solu-
ble P-selectin from platelets or alternatively from the 1999 by the International Society of Nephrology
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binding of cP-selectin pre-existent in the blood. It is Rationale for the use of SNP
therefore conceivable that contact of blood with artificial Sodium nitroprusside, a potent vasodilator, reversibly
surfaces does not only cause hematological phenomena inhibits platelet function and P-selectin expression on
such as an HD-associated decrease in circulating plate- platelets [24]. SNP is nonenzymatically degraded and
lets [13, 15] and leukocytes, by a P-selectin/CD15s inter- thereby directly releases NO. In turn, NO enhances the
action [12], but that it may also play an important role activity of guanylate cyclase by formation of S-nitrosothi-
in dialysis-associated platelet dysfunction [16, 17], pul- ols and thus the intracellular concentration of cyclic gua-
monary dysfunction [18, 19], and propagation of athero- nosyl monophosphate. Because of the rapid reversible
sclerosis [20]. platelet inhibition (duration of pharmacodynamic action
Thus, it seems important to investigate therapeutic on platelet aggregation of less than 8 min), the short
avenues that down-regulate dialysis-induced platelet ac- half-life, the direct NO release, and the dialysance of
tivation: Nitric oxide (NO) inhibits platelet aggregation, SNP, it was assumed to be the ideal candidate for this
activation, secretion and adhesion [21–23]. Recently, it experimental protocol.
has convincingly been shown in various models that NO
effectively [21–23] and reversibly [24] suppresses platelet Rationale for the dosage
activation and P-selectin expression, whereas inhibition The dose of 1 mg/kg/min SNP is within the lower dose
of NO synthesis [25] has the opposite effect in that it range for treatment of cardiovascular indications (0.5 to
enhances P-selectin expression on platelets. Hence, a 8 mg/kg/min up to 3 days). Harris et al have observed a
NO donor may be an ideal model drug to down-regulate 50% decrease in epinephrine-induced platelet aggrega-
HD-associated platelet activation. tion ex vivo, under the maximally tolerated systemic SNP
Based on these findings [24–27], we hypothesized that dose of approximately 10 mg/kg/min [24]. We did not
increasing the NO supply to platelets may inhibit their infuse SNP systemically but through the inlet port of the
activation induced by contact with artificial surfaces such dialyzer. Considering a flow rate of approximately 300
as dialysis membranes, as evidenced by diminished P- ml/min in the inlet-line, SNP probably reached approxi-
selectin expression and reduced formation of platelet- mately 15-fold to 20-fold higher concentrations in the
neutrophil aggregates. Hence, we studied whether NO
dialyzer than it would have reached when infused into
generated from sodium nitroprusside (SNP) may blunt
the systemic circulation. Thus, this dose was likely appro-
HD-associated platelet activation. If NO turned out to
priate to inhibit platelet function in the dialyzer circuitbe effective in this respect, it could become a useful
(because it was equivalent to a dose of 15 to 20 mg/kg/adjuvant in preventing HD-associated complications
min administered systemically).such as dialysis-associated platelet dysfunction, pulmo-
nary dysfunction, and atherosclerosis. Patients
Twelve patients were included in the feasibility study.
METHODS Based on the results from the feasibility study, we chose
to study the same number of patients in the main trial,Study design
because it was calculated that 12 patients would be ade-The study protocol was approved by the Ethics Com-
quate to detect a 50% lower P-selectin expression undermittee of the Vienna University Hospital. Written con-
SNP as compared with placebo.sent was obtained from all patients prior to their inclu-
Eligible for inclusion in this study were patients rou-sion in the study. The aim of the feasibility study was to
tinely undergoing HD because of end-stage renal dis-determine an adequate sample size for the main outcome
ease, aged between 19 and 80 years.variable (P-selectin1 platelets) in the subsequent interven-
Exclusion criteria were hypotension (sitting diastolictional trial and was therefore conducted as an open pro-
of less than 60 mm Hg/systolic blood pressure of lessspective trial. The main trial was a randomized, double-
than 100 mm Hg), history of migraine in the last monthblind, placebo-controlled, two-way, cross-over study with
or history of symptomatic cerebrovascular disease.a washout period of one week.
Experimental proceduresThe main study
In the feasibility study, no drug was administered.The aims of the interventional trial were to compare
Twelve patients with end-stage renal disease undergoingthe effect of standard HD with the effect of dialysis under
maintenance HD were enrolled. A total of five bloodthe influence of increased NO generation (by local SNP
samples (7 ml each) was drawn into citrated Vacutainertinfusion into the inlet port of the dialyzer) on changes in
tubes. The total blood loss on the study day was 35P-selectin expression on platelets and platelet-leukocyte
ml. Blood samples were obtained at the following timeaggregate formation and on the dialysis-induced changes
in leukocyte and platelet counts. points: (1) from the inlet-line at the start of dialysis at
Jilma et al: NO and platelet activation during HD688
zero minutes, (2 1 3) from the inlet line and the outlet P-selectin mAb directed against the low-density antigen
line at five minutes, and (4 1 5) from the inlet line and (CD62P) was used simultaneously with a phycoerythrin
the outlet line at 15 minutes. (PE)-labeled anti-CD41 mAb directed against the high-
These sampling times were selected because maximal density antigen (CD41, which was used as a gate control)
activation of platelets and leukocytes has previously for double staining: 6 ml of undiluted FITC-labeled anti-
been observed at those time points [9, 12, 13, 28]. P-selectin mAb and 6 ml of PE-labeled anti-CD41 were
In the interventional study, 12 patients, aged 51 years added to 20 ml of diluted whole blood and were incubated
(range 34 to 67), with a body mass index of 23.7 kg/m2 for five minutes at room temperature. The incubation was
(range 20.2 to 28.6 kg/m2) were included. Patients were terminated by addition of 750 ml of ice-cold phosphate-
treated for an average of three years (range, 1 to 6 years) buffered saline, and samples were put on ice; the flow
with HD. Blood flow in the HD device was 326 ml/min cytometric analysis was started immediately thereafter.
(CI, 260 to 393 ml/min). Blood samples were obtained An isotype-specific mAb was used to set a threshold for
as described earlier here. Patients were randomized to P-selectin–positive platelets. We analyzed 25,000 plate-
receive a 15-minute infusion of SNP (Nipruss; Sanol- lets per sample with LYSIS II software on a FACScan
Schwarz, Monheim BRD, Austria; 1 mg/kg/min dissolved flow cytometer (Becton Dickinson, San Jose, CA, USA).
in glucose 5%, infusion rate 2 ml/min) into the inlet port Data are presented as the percentage of P-selectin–
of the HD device, or alternatively glucose (Glucose 5%, positive platelets. The method for determining platelet-
Leopold Infusionsflaschet; Leopold Pharma, Vienna, leukocyte aggregates during HD has been performed as
Austria). SNP and placebo infusions were protected from Gawaz et al originally described to allow better compari-
light by using dark orange syringes, which were wrapped son between studies [13]. However, data are presented as
in aluminum foil, and by black infusion lines. This was percentage CD411 neutrophils rather than CD41 mean
done to protect SNP from degradation and to prevent fluorescence intensity of neutrophils. Flow cytometric
unblinding of the investigator by the yellow color of SNP analysis of neutrophils was performed as previously out-
in solution. This procedure and lot number of SNP were lined [33]. Soluble P-selectin was measured by enzyme
shown to enhance the decrease in blood pressure during immunoassay (R & D Systems, Oxon, UK) as described
extracorporeal circulation on a cell separator [29]. After previously [34]. Plasma levels of F112 were determined bya minimum of eight days, patients crossed over to the enzyme immunoassay (Enzygnost F112; Behringwerke,alternative treatment protocol. As a general restriction, Germany) [35, 36].
timing of erythropoietin administration (N 5 3) had to
be exactly the same before or on both study days. The Biometrics
dialyzer membranes used were NiproFB-210UGA (Tri-
Because of non-normal distribution, all data wereacetate; Nisho Corp., Osaka, Japan), F60S and F80S (Poly-
compared with nonparametric statistics. The Friedmansulfone; Fresenius, Bad Homburg, Germany; N 5 4 each)
analysis of variance and the Wilcoxon signed ranks testand were not switched between periods. Anticoagulation
were used. Data are expressed as means and the 95%was achieved by means of a loading dose of heparin and
confidence intervals. A two-tailed P value of less thana constant infusion of heparin.
0.05 was considered statistically significant.Blood was collected from the arterial inlet and the
venous outlet lines of the hemodialyzer through a 21-
gauge cannula into citrated Vacutainer tubes. All anti- RESULTS
bodies were monoclonal (mAb) and were purchased Effects of hemodialysis on P-selectin expression
from Immunotech (Coulter, Vienna, Austria). Flow cy- of platelets
tometric analysis of platelets was performed as pre-
P-selectin expression increased within five minutes afterviously described [3, 30]. Platelets were not fixed, and
start of HD. In the pilot study, the number of P-selectin1blood was therefore processed immediately to avoid stor-
platelets increased from 2.1% (CI, 1.0 to 3.1%) by 1.0%age-associated activation [31]. Whole blood was diluted
(CI, 0.0 to 1.9%) (Fig. 1). This was internally consistentwith phosphate-buffered saline to a final concentration
with the findings in the main trial. Due to one outlierof 20 3 109 platelets/liter in FALCON 2052 polystyrene
who showed an increase in P-selectin1 platelets from 6%12 3 75 mm tubes (Becton Dickinson, San Jose, CA,
to 27% in the SNP period, there was a larger variabilityUSA). Twenty microliters of this dilution were incubated
in the SNP period. When this outlier is excluded fromwith 10 ml of phosphate-buffered saline without or with
analysis, the number of P-selectin–positive platelets in-histamine 0.9 m as a positive control (yielding an average
creased by 1.3% (CI, 20.1 to 2.7, P 5 0.02 vs. baseline)of 30% P-selectin positive platelets) for 10 minutes at
in the placebo period and by 1.1% (20.1 to 2.3%, P 5room temperature. Expression of CD62 on platelets was
0.04 vs. baseline) in the SNP period. Hence, treatmentdetermined in accordance with a recent consensus article
[32]. A fluorescein-isothiocyanate (FITC)–labeled anti- with SNP did not inhibit platelet activation.
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Formation of platelet-neutrophil aggregates
Baseline CD411 neutrophils averaged 4.5% (CI, 3.2
to 5.8%) and 5.4% (CI, 2.8 to 7.9%) in the placebo and
the SNP period, respectively. A drop in CD411 neutro-
phils occurred within five minutes: 20.4% (CI, 21.3 to
0.5%; P . 0.05) and 21.3% (CI, 22.7 to 20.1%; P 5
0.02) in the placebo and the SNP periods, respectively.
At 15 minutes, the arteriovenous differences in CD411
neutrophils averaged 0.2% (CI, 20.5 to 0.8; P . 0.05)
and 1.6% (CI, 20.2 to 3.3%; P 5 0.03) in the placebo
and the SNP periods, respectively.
Changes in soluble P-selectin across the
hemodialysis device
Soluble P-selectin levels averaged 59 ng/ml (CI, 49 to
70) and 68 ng/ml (CI, 48 to 87) in the placebo and the
SNP periods, respectively. The levels of soluble P-selec-
tin were only slightly higher in the venous outlet: 6%
(95% CI, 0 to 12, P 5 0.06) and 9% (CI, 23 to 21%,
P 5 0.024) during the placebo and the SNP periods,
respectively. No differences between treatment periods
were observed (P . 0.05, data not shown).
Changes in plasma levels of F112 across the
hemodialyzer
Baseline values of F112 averaged 2.3 nmol/liter (CI,
1.6 to 3.1) in the placebo period and 2.3 nmol/liter (CI,
1.3 to 3.2) in the SNP period. There was a moderate
arteriovenous increase in F112 plasma levels across the
dialyzer at 15 minutes: 0.8 nmol/liter (CI, 0.0 to 1.7, P 5 Fig. 1. Changes in the percentage of P-selectin1 platelets (top layer)
and platelet-neutrophil aggregates (CD411 neutrophils; bottom layer)0.038) and 0.8 nmol/liter (CI, 0.2 to 1.4, P 5 0.004) in
during HD with (j) and without (s) infusion of sodium nitroprussidethe placebo period and the SNP period, respectively. (SNP) into the inlet port. SNP did not prevent HD-induced platelet
activation. Data are expressed as mean and the 95% confidence inter-
Changes in blood pressure vals. The dotted line indicates the mean values obtained during the
pilot trial. *P , 0.05 vs. baseline. *P , 0.05 for arteriovenous difference.Although there was a minor (less than 5%) decrease
in diastolic blood pressure at five minutes in both periods,
there was no consistent or significant decrease in blood
pressure after infusion of SNP (data not shown). increase in platelet activation. Contrary to the hope that
motivated the design of this study, we found that SNPChanges in differential blood counts
infusion did not inhibit platelet activation as measured
All changes were corrected for hemoconcentration by P-selectin expression on platelets.
that occurred across the hemodialyzer (Fig. 2). Baseline Numerous studies have demonstrated the ability of
neutrophil counts averaged 3.8 3 109/liter (CI, 2.8 to 4.7)
NO and SNP to inhibit platelet activation [24–27]. Thus,
and 3.3 3 109/liter (CI, 2.5 to 4.1) in the placebo and
we have no ready explanation for the lack of effect ofSNP periods, respectively. Five minutes after the start
SNP. However, the question arises as to whether theof HD, neutrophil counts dropped by 21.5 3 109/liter
dose of SNP was adequate. The dose was selected on(CI, 22.5 to 20.5) and by 21.0 3 109/liter (CI, 21.7 to
the basis of results from previous studies with SNP. Infu-
20.3) in the placebo and the SNP periods, respectively
sion of SNP (40 mg/min) decreased diastolic blood pres-(P , 0.005). However, no significant changes in platelet
sure only slightly during the first 15 minutes during plate-counts were observed (P . 0.05).
letpheresis, which is in good agreement with this study
[29]. However, marked hypotensive effects were re-
DISCUSSION corded after one hour of SNP infusion [29]. In another
study, SNP infusion (1 mg/kg/min) did not cause anyThe aim of this investigation was to test whether an
increase in NO supply would inhibit the HD-induced adverse events in healthy subjects not undergoing extra-
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corporeal circulation, although it induced significant he-
modynamic effects [37]. Doubling of the dose induced
side effects such as headache or dizziness even in healthy
subjects. Taking possible hypotensive effects of HD into
account, we assumed that the lower dose would be better
tolerated by our patients. Considering a flow rate of
approximately 300 ml/min in the inlet port, SNP levels
were probably 20-fold higher in the dialyzer than SNP
concentrations expected after systemic infusion. Thus,
we calculated that a dose of 1 mg/kg/min administered
into the inlet port of the dialyzer would be equipotent
to 20 mg/kg/min administered systemically. This was
deemed adequate, since a maximally tolerated systemic
SNP dose of approximately 10 mg/kg/min decreased the
epinephrine-induced platelet aggregation ex vivo by 50%.
The discrepancy may be explained by the fact that not
only a single but a multitude of stimulators of platelet
activation (such as thrombin or adenosine diphosphate)
may become operative in HD-induced platelet activa-
tion. This is underscored by the finding that NO is a
more potent inhibitor of epinephrine than thrombin-
induced platelet activation [38], which increased across
the hemodialyzer. It should also be emphasized that the
inhibitory effects of NO on platelet activation may be
compromised in the presence of hemoglobin (whole
blood as opposed to platelet-rich plasma). Finally, Lang-
ford et al’s study [39] and our data [29] demonstrate that
NO donors are ineffective in inhibiting platelet activation
during extracorporeal circulation, such as cardiopulmo-
nary bypass or cell separators.
The second issue that has to be considered is the sam-
Fig. 2. Changes in hemoconcentration (top layer), corrected platelet
ple size, which was based on the pilot study in 12 patients counts (middle layer), and corrected neutrophil counts (bottom layer)
undergoing HD, showing approximately a 50% increase during HD with (j) and without (h) infusion of sodium nitroprusside
(SNP) into the inlet port. SNP did not prevent HD-induced neutropeniain P-selectin expression during HD. Repeat samples from
(P , 0.005 vs. baseline in both periods). Data are expressed as meanthe same subjects showed a coefficient of variation of and the 95% confidence intervals.
10% in the degree of P-selectin expression [3]. Thus,
although we had the power to detect a relatively large
effect of SNP, minor effects of SNP may have gone
Reprint requests to Bernd Jilma, M.D., Department of Clinical Phar-undetected because of the day-to-day variability in the
macology-TARGET, The Adhesion Research Group Elaborating Ther-
response of individual patients to HD. apeutics, Vienna University Hospital School of Medicine, Wa¨hringer
Gu¨rtel 18–20, A-1090 Wien, Austria.Regardless of what may be regarded as a clinically
E-mail: Bernd.Jilma@univie.ac.atrelevant suppression of P-selectin expression, Figure 1
shows that there was not even a trend toward decreased
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